OptimizeRx Shares Tumble on Cut to Outlook, Despite 3Q Beat

Dow Jones11-12

Shares of OptimizeRx Corporation tumbled after the company cut its guidance, even as its third-quarter results exceeded analyst expectations.

On Thursday premarket, OptimizeRx plunged nearly 22%.

The healthcare technology company said it now expects full-year revenue between $87 million and $93 million, down from an earlier projection of revenue between $95 million to $100 million.

Analysts polled by FactSet currently expect $96.2 million in full-year revenue.

"While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season," Chief Executive Stephen Silvestro said.

The company's third-quarter profit came in at $1.2 million, or 6 cents a share, compared with a profit of around $779,000, or 4 cents a share, a year earlier.

Stripping out certain one-time items, adjusted earnings were 20 cents a share. Analysts were expecting 16 cents a share.

Revenue fell to $21.6 million from $26.1 million a year prior. Analysts were expecting $21.2 million.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment